Insider Trading Alert - CFN, INFN, RGR, GLUU And ALKS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 10, 2014, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $8,688,240.00.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Gallahue Kieran who is Chairman and CEO at CareFusion sold 25,000 shares at $41.05 on Jan. 10, 2014. Following this transaction, the Chairman and CEO owned 122,873 shares meaning that the stake was reduced by 16.91% with the 25,000-share transaction.

The shares most recently traded at $41.38, up $0.33, or 0.8% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 1,250
  • 12-Week # shares sold: 38,750
  • 24-Week # shares sold: 102,050

The average volume for CareFusion has been 1.4 million shares per day over the past 30 days. CareFusion has a market cap of $8.7 billion and is part of the health care sector and health services industry. Shares are up 3.52% year-to-date as of the close of trading on Friday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 24.1. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Infinera Corporation (INFN) - FREE Research Report

Welch David F who is President at Infinera Corporation sold 50,000 shares at $10.00 on Jan. 10, 2014. Following this transaction, the President owned 799,493 shares meaning that the stake was reduced by 5.89% with the 50,000-share transaction.

The shares most recently traded at $9.25, down $0.75, or 8.14% since the insider transaction. Historical insider transactions for Infinera Corporation go as follows:

  • 4-Week # shares sold: 12,500
  • 12-Week # shares sold: 12,500
  • 24-Week # shares sold: 75,000

The average volume for Infinera Corporation has been 1.4 million shares per day over the past 30 days. Infinera Corporation has a market cap of $1.1 billion and is part of the technology sector and telecommunications industry. Shares are down 5.11% year-to-date as of the close of trading on Friday.

Infinera Corporation provides optical networking equipment, software, and services to communications service providers, Internet content providers, cable operators, and subsea network operators worldwide. Currently there are 4 analysts that rate Infinera Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INFN - FREE

TheStreet Quant Ratings rates Infinera Corporation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Infinera Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sturm Ruger & Company (RGR) - FREE Research Report

Fifer Michael O who is Ceo at Sturm Ruger & Company sold 14,597 shares at $79.05 on Jan. 10, 2014. Following this transaction, the Ceo owned 8,395 shares meaning that the stake was reduced by 63.49% with the 14,597-share transaction.

The shares most recently traded at $83.78, up $4.73, or 5.65% since the insider transaction. Historical insider transactions for Sturm Ruger & Company go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 30,737
  • 24-Week # shares sold: 40,269

The average volume for Sturm Ruger & Company has been 325,900 shares per day over the past 30 days. Sturm Ruger & Company has a market cap of $1.5 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 10.21% year-to-date as of the close of trading on Friday.

Sturm, Ruger & Company, Inc. engages in the design, manufacture, and sale of firearms in the United States. The company offers single-shot, auto loading, bolt-action, and sporting rifles; single-action and double-action revolvers; and rim fire auto loading and center fire auto loading pistols. The stock currently has a dividend yield of 2.9%. The company has a P/E ratio of 15.2. Currently there are no analysts that rate Sturm Ruger & Company a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RGR - FREE

TheStreet Quant Ratings rates Sturm Ruger & Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Sturm Ruger & Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Glu Mobile (GLUU) - FREE Research Report

Nada Hany who is Director at Glu Mobile sold 400,000 shares at $4.23 on Jan. 10, 2014. Following this transaction, the Director owned 85,880 shares meaning that the stake was reduced by 82.32% with the 400,000-share transaction.

The shares most recently traded at $4.13, down $0.10, or 2.53% since the insider transaction.

The average volume for Glu Mobile has been 3.4 million shares per day over the past 30 days. Glu Mobile has a market cap of $334.4 million and is part of the technology sector and computer software & services industry. Shares are up 7.45% year-to-date as of the close of trading on Friday.

Glu Mobile Inc. develops and publishes a portfolio of action/adventure and casual games for the users of smartphones and tablet devices. Currently there are 6 analysts that rate Glu Mobile a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GLUU - FREE

TheStreet Quant Ratings rates Glu Mobile as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full Glu Mobile Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alkermes (ALKS) - FREE Research Report

Bloom Floyd E who is Director at Alkermes sold 10,000 shares at $43.06 on Jan. 10, 2014. Following this transaction, the Director owned 100,281 shares meaning that the stake was reduced by 9.07% with the 10,000-share transaction.

The shares most recently traded at $46.24, up $3.18, or 6.87% since the insider transaction. Historical insider transactions for Alkermes go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 39,976
  • 24-Week # shares sold: 39,976

The average volume for Alkermes has been 891,500 shares per day over the past 30 days. Alkermes has a market cap of $5.9 billion and is part of the health care sector and drugs industry. Shares are up 10.99% year-to-date as of the close of trading on Friday.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company has a P/E ratio of 307.5. Currently there are 4 analysts that rate Alkermes a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALKS - FREE

TheStreet Quant Ratings rates Alkermes as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Alkermes Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes